One motivation to generate bispecific cs130Fc variants was based on these recent data suggesting that selective inhibition of trans-signaling might be superior over simultaneous blocking of classic and trans-signaling by IL-6R antibodies in IBD. The gene discussed is IL6R; the disease is inflammatory bowel disease.